Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + Temozolomide +/- Radiotherapy in Newly Diagnosed Glioblastoma
NCT06095375Phase 1Completed
- Sponsor
- Istituto Oncologico Veneto
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of regorafenib in glioblastoma (GBM) (2 cohorts), sponsored by Istituto Oncologico Veneto. Primary endpoints: Dose Limiting Toxicity, Adverse Events and 1 more. Started Jul 2022; status: completed.
02
Drugs
regorafenib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06095375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095375.